Literature DB >> 27345983

Generation of KCL028 research grade human embryonic stem cell line carrying a mutation in the HTT gene.

Laureen Jacquet1, Heema Hewitson1, Victoria Wood1, Neli Kadeva1, Glenda Cornwell1, Stefano Codognotto1, Carl Hobbs2, Emma Stephenson1, Dusko Ilic3.   

Abstract

The KCL028 human embryonic stem cell line was derived from an embryo donated for research that carried an autosomal dominant mutation affecting one allele of the HTT gene encoding huntingtin (43 trinucleotide repeats; 21 for the normal allele). The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin fibroblasts. Both the derivation and cell line propagation were performed in an animal product-free environment. Pluripotent state and differentiation potential were confirmed by in vitro and in vivo assays.
Copyright © 2016 University of Texas at Austin Dell Medical School. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27345983      PMCID: PMC4823669          DOI: 10.1016/j.scr.2016.01.006

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


Resource table

Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122–128. Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366–1381. Jacquet, L., Neueder, A., Földes, G., Karagiannis, P., Hobbs, C., Jolinon, N., Mioulane, M., Sakai, T., Harding, S.E., Ilic, D., 2015. Three Huntington's disease specific mutation-carrying human embryonic stem cell lines have stable number of CAG repeats upon in vitro differentiation into cardiomyocytes. PLoS One. 10(5), e0126860. http://doi.org/10.1371/journal.pone.0126860

Resource details

We generated KCL028 research grade hESC line following protocols, established previously (Ilic et al., 2012, Stephenson et al., 2012). The expression of the pluripotency markers was tested after freeze/thaw cycle (Ilic et al., 2012). Differentiation potential into three germ layers was verified in vitro (Jacquet et al., 2015) and in vivo (Jacquet et al., 2015).

Materials and methods

Consenting process

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in the meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (PGD-V.8) were created on Jul. 01, 2010. HFEA Code of Practice that was in effect at the time of document creation: Edition 8 – R.2 (http://www.hfea.gov.uk/2999.html). The donor couple signed the consent on Jan. 12, 2011. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8 – R.2. HFEA Code of Practice Edition 8 – R.2 was in effect: Apr. 07, 2010–Apr. 06, 2011.

Embryo culture and micromanipulation

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details (Ilic et al., 2012, Stephenson et al., 2012). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

Cell culture

ICM plated on mitotically inactivated HFF were cultured as described (Ilic et al., 2012, Stephenson et al., 2012). TE cells were removed mechanically from outgrowth (Ilic et al., 2007, Ilic et al., 2010). hESC colonies were expanded and cryopreserved at the third passage.

Viability test

Straws with the earliest frozen passage (p. 2–3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

Pluripotency markers

Pluripotency was assessed using two different techniques: enzymatic activity assay [alkaline phosphatase (AP) assay] and immunostaining as described (Ilic et al., 2012, Stephenson et al., 2012, Petrova et al., 2014).

Differentiation

Spontaneous differentiation into three germ layers was assessed in vitro as described (Ilic et al., 2012, Stephenson et al., 2012, Petrova et al., 2014) and in vivo (Jacquet et al., 2015). Targeted differentiation in cardiomyocytes followed the protocols described earlier (Jacquet et al., 2015, Laflamme et al., 2007).

Genotyping

DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer's instructions. Amplification of polymorphic microsatellite markers was carried out as described (Ilic et al., 2012). Allele sizes were recorded to give a unique fingerprint of each cell line.

Array comparative genomic hybridization (aCGH)

aCGH was performed as described in details (Ilic et al., 2012).

HLA typing

HLA-A, -B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).

Author disclosure statement

There are no competing financial interests in this study.
Name of stem cell lineKCL028
InstitutionKing's College London, London UK
Derivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma Stephenson
Contact person and emailDusko Ilic, email: dusko.ilic@kcl.ac.uk
Date archived/stock dateMay 25, 2011
Type of resourceBiological reagent: cell line
Sub-typeHuman pluripotent stem cell line
OriginHuman embryo
Key marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activity
AuthenticationIdentity and purity of line confirmed
Link to related literature (direct URL links and full references)

Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122–128.

doi: 10.3109/14653249.2011.623692http://www.ncbi.nlm.nih.gov/pubmed/22029654

Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366–1381.

doi: 10.1038/nprot.2012.080http://www.ncbi.nlm.nih.gov/pubmed/22722371

Jacquet, L., Neueder, A., Földes, G., Karagiannis, P., Hobbs, C., Jolinon, N., Mioulane, M., Sakai, T., Harding, S.E., Ilic, D., 2015. Three Huntington's disease specific mutation-carrying human embryonic stem cell lines have stable number of CAG repeats upon in vitro differentiation into cardiomyocytes. PLoS One. 10(5), e0126860.

http://doi.org/10.1371/journal.pone.0126860

http://www.ncbi.nlm.nih.gov/pubmed/25993131
Information in public databasesKCL028 is a National Institutes of Health (NIH) registered hESC lineNIH registration number: 0224NIH approval number: NIHhESC-13-0224http://grants.nih.gov/stem_cells/registry/current.htm?id=664
EthicsThe hESC line KCL028 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.
Consent signedJan 27, 2011
Embryo usedMay 04, 2011
UK Stem Cell Bank deposit approvalDec 01, 2011Reference: SCSC11-47
SexMale 46, XY
GradeResearch
Disease status (Fig. 1)Mutation affecting one allele of the HTT gene encoding huntingtin (~ 43 CAG repeats; 21 for the normal allele) associated with Huntington's disease (Ilic et al., 2015)
Karyotype (aCGH)No imbalance detected.
DNA fingerprintAllele sizes (in bp) of 17 microsatellite markers specific for chromosomes 13, 18 and 21 (Jacquet et al., 2015)
HLA typingHLA-1: 02,03; − B:07,35, − C: 04,07; Bw: 6; DRB1: 01; DQB1: 05
Viability testingPass
Pluripotent markers (immunostaining)(Fig. 2)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity (Jacquet et al., 2015)
Three germ layers differentiation in vitro (immunostaining)(Fig. 3)Endoderm: AFP (α-fetoprotein); Ectoderm: TUBB3 (tubulin, β3 class III); Mesoderm: ACTA2 (actin, α2, smooth muscle) (Jacquet et al., 2015)
Three germ layer differentiation in vivo (teratomas)(Fig. 4)Endoderm: AFP, GATA4. Ectoderm: TUBB3, GFAP (glial fibrillary acidic protein). Mesoderm: DES (desmin), Alcian Blue and periodic acid–Schiff (PAS)-stained cartilage (Jacquet et al., 2015)
Targeted differentiationCardiomyocytes: TNNT2 (cardiac troponin T) immunostaining
Sibling lines availableKCL027
  8 in total

1.  Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment.

Authors:  Emma Stephenson; Laureen Jacquet; Cristian Miere; Victoria Wood; Neli Kadeva; Glenda Cornwell; Stefano Codognotto; Yaser Dajani; Peter Braude; Dusko Ilic
Journal:  Nat Protoc       Date:  2012-06-21       Impact factor: 13.491

2.  Derivation of hESC from intact blastocysts.

Authors:  Dusko Ilic; Olga Genbacev; Ana Krtolica
Journal:  Curr Protoc Stem Cell Biol       Date:  2007-06

3.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

4.  Effect of karyotype on successful human embryonic stem cell derivation.

Authors:  Dusko Ilic; Eduardo Caceres; Shuzhuang Lu; Patty Julian; Russell Foulk; Ana Krtolica
Journal:  Stem Cells Dev       Date:  2010-01       Impact factor: 3.272

5.  Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions.

Authors:  Dusko Ilic; Emma Stephenson; Victoria Wood; Laureen Jacquet; Danielle Stevenson; Anastasia Petrova; Neli Kadeva; Stefano Codognotto; Heema Patel; Maxine Semple; Glenda Cornwell; Caroline Ogilvie; Peter Braude
Journal:  Cytotherapy       Date:  2011-10-27       Impact factor: 5.414

6.  Strategy for the creation of clinical grade hESC line banks that HLA-match a target population.

Authors:  Laureen Jacquet; Emma Stephenson; Robert Collins; Heema Patel; Jane Trussler; Roaa Al-Bedaery; Pamela Renwick; Caroline Ogilvie; Robert Vaughan; Dusko Ilic
Journal:  EMBO Mol Med       Date:  2012-11-19       Impact factor: 12.137

7.  Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.

Authors:  Laureen Jacquet; Andreas Neueder; Gabor Földes; Panagiotis Karagiannis; Carl Hobbs; Nelly Jolinon; Maxime Mioulane; Takao Sakai; Sian E Harding; Dusko Ilic
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

8.  3D In vitro model of a functional epidermal permeability barrier from human embryonic stem cells and induced pluripotent stem cells.

Authors:  Anastasia Petrova; Anna Celli; Laureen Jacquet; Dimitra Dafou; Debra Crumrine; Melanie Hupe; Matthew Arno; Carl Hobbs; Aleksandra Cvoro; Panagiotis Karagiannis; Liani Devito; Richard Sun; Lillian C Adame; Robert Vaughan; John A McGrath; Theodora M Mauro; Dusko Ilic
Journal:  Stem Cell Reports       Date:  2014-04-24       Impact factor: 7.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.